ERBB2 and breast carcinoma: This discovery has led to the invention of targeted therapies that specifically disrupt the ability of these proteins to dimerize, and with some success; e.g., a monoclonal antibody for EGFR, cetuximab, is now used alongside chemotherapy for certain colorectal and head & neck tumors, and trastuzumab is used to target HER2 in some breast cancers [37].